 Current therapy for Von Willebrand disease includes desmopressin acetate DDAVP and or VWFFVIII concentrates. Patients with severe Von Willebrand disease face a lifetime of weekly treatments and mounting medical bills. Gene therapy could help these patients improve their quality of life by providing the missing factors necessary for the bloods ability to clot properly. 